Breaking News Instant updates and real-time market news.

ENPH

Enphase Energy

$1.13

0.02 (1.80%)

, AKAO

Achaogen

$15.46

0.47 (3.14%)

17:51
01/10/17
01/10
17:51
01/10/17
17:51

On The Fly: After Hours Movers

HIGHER: Enphase Energy (ENPH), up 14.2% after it announced a $10M strategic investment from T.J. Rodgers and John Doerr... Achaogen (AKAO), up 8.6% after Baker Bros. Advisors reported a 13.1% passive stake in the company... Ichor Holdings (ICHR), up 8.1% after it reported better than expected preliminary revenue for the fourth quarter and fiscal 2016... Merck (MRK), up 3.9% after its KEYTRUDA supplemental Biologics License Application received priority review from the FDA... United Continental (UAL), up 2.5% after it reported preliminary December and fourth quarter traffic data... MagnaChip (MX), up 0.8% after its preliminary Q4 revenue beat estimates. LOWER: Bluerock Residential (BRG), down 4.6% after it commenced an offering of 4M shares of Class A common stock... Parsley Energy (PE), down 4.3% after it announced an offering of 20M shares of Class A common stock... Veeco (VECO), down 3% after filed to sell $200M of Convertible Senior Notes due 2023 and after it reported preliminary results for Q4 and FY16... Juniper (JNPR), down 2.4% after the stock was downgraded to Sell from Hold at Deutsche Bank... Valeant (VRX), down 0.4% after it reiterated its guidance for FY16.

ENPH

Enphase Energy

$1.13

0.02 (1.80%)

AKAO

Achaogen

$15.46

0.47 (3.14%)

ICHR

Ichor Holdings

$13.40

-0.6 (-4.29%)

MRK

Merck

$59.92

-1.18 (-1.93%)

UAL

United Continental

$73.66

2.38 (3.34%)

MX

MagnaChip

$6.35

0.25 (4.10%)

BRG

Bluerock Residential

$13.84

-0.01 (-0.07%)

PE

Parsley Energy

$36.67

0.91 (2.54%)

VECO

Veeco

$29.65

0.55 (1.89%)

JNPR

Juniper

$28.40

0.01 (0.04%)

VRX

Valeant

$16.40

1.05 (6.84%)

  • 10

    Jan

  • 10

    Jan

  • 19

    Jan

  • 26

    Jan

  • 01

    Feb

  • 02

    Feb

  • 09

    Feb

  • 16

    Feb

  • 21

    Feb

  • 08

    Mar

  • 27

    May

ENPH Enphase Energy
$1.13

0.02 (1.80%)

11/02/16
11/02/16
UPGRADE

Outperform
Enphase Energy upgraded on growth, market share gains at Avondale
As previously reported, Avondale upgraded Enphase Energy to Outperform from Market Perform with a $4.50 price target saying Q4 is setting up to be an inflection point for the company. Analyst Michael Morosi believes a bottom is likely in for both market share and gross margins, and major product launches in FY17-18 will enable the company to continue to progress. The analyst said recent restructuring initiatives helped fortify the balance sheet and the company to return to mid-20s gross margins and $400M+ revenues in FY18.
11/02/16
11/02/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Square (SQ) upgraded to Outperform from Neutral at Credit Suisse with analyst Paul Condra raising estimates to reflect the company's solid third quarter results. Condra continues to believe Square is exposed to strong secular headwinds and its years of product investment and brand building put it ahead of the competition. 2. Enphase Energy (ENPH) upgraded to Outperform from Perform at Oppenheimer and to Outperform from Market Perform at Avondale. 3. Etsy (ETSY) upgraded to Buy from Neutral at Roth Capital with analyst Darren Aftahi saying he believes inherent operating leverage and the international opportunity in Etsy's model is "too compelling." 4. Mosaic (MOS) upgraded to Buy from Outperform at CLSA with analyst Mark Connelly citing valuation and stabilizing results. 5. Quotient Technology (QUOT) upgraded to Outperform from Sector Perform at RBC Capital and to Buy from Hold at Maxim. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/05/16
CHLM
12/05/16
INITIATION
Target $4
CHLM
Buy
Enphase Energy initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Brad Meikle initiated Enphase Energy with a Buy rating and $4 price target.
11/02/16
AVON
11/02/16
UPGRADE
AVON
Outperform
Enphase Energy upgraded to Outperform from Market Perform at Avondale
AKAO Achaogen
$15.46

0.47 (3.14%)

12/12/16
NEED
12/12/16
UPGRADE
NEED
Buy
Achaogen upgraded to Buy from Hold at Needham
01/04/17
LEER
01/04/17
INITIATION
Target $21
LEER
Outperform
Achaogen initiated with an Outperform at Leerink
Leerink analyst Paul Matteis started Achaogen with an Outperform rating and $21 price target as he believes the level of unmet need presented by carbapenem-resistant enterobacteriaceae, combined with clinical/microbiological superiority data for its lead product plazomicin, may drive relatively faster uptake.
12/13/16
12/13/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. CBS (CBS) upgraded to Outperform from Market Perform by BMO Capital analyst Daniel Salmon after Viacom (VIA) announced that it was no longer pursuing a merger. 2. Goldman analyst Matthew Borsch upgraded Molina Healthcare (MOH) to Buy and raised its price target to $65 from $59 citing attractive valuation and believes 2017 results will be more stable and stronger than expectations, particularly if ACA Medicaid coverage is maintained. 3. Janney Capital analyst Tyler Batory upgraded SeaWorld (SEAS) to Buy from Neutral based on his expectation for better performance from its Orlando park. 4. Goldman Sachs analyst Terence Flynn upgraded Ophthotech (OPHT) to Neutral after the stock ended yesterday down 86%. However, he sees a low likelihood that the company's trial testing a Fovista combo with Eylea or Avastin will be positive. 5. Achaogen (AKAO) upgraded to Buy from Hold at Needham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/13/16
WBLR
12/13/16
NO CHANGE
Target $25
WBLR
Outperform
Achaogen price target raised to $25 from $11 at William Blair
William Blair analyst Y. Katherine Xu raised her price target for Achaogen to $25 saying yesterday's positive top-line results from the Phase III registrational studies exceeded her expectations. The analyst raised her after probability of commercialization in the urinary tract infection and antibiotic resistant enterobacteriaceae settings to 95% from 85% and 70%, respectively, and upped her worldwide sales for plazomicin to $540M from $350M. Xu maintains an Outperform rating on Achaogen. After rallying 148% yesterday, the stock is up 13% to $14.75 in pre-market trading.
ICHR Ichor Holdings
$13.40

-0.6 (-4.29%)

01/03/17
RBCM
01/03/17
INITIATION
RBCM
Outperform
Ichor Holdings initiated with an Outperform at RBC Capital
RBC Capital analyst Amit Daryanani started coverage of Ichor Holdings with a $14 price target and an Outperform rating
01/03/17
NEED
01/03/17
INITIATION
Target $17
NEED
Buy
Ichor Holdings initiated with a Buy at Needham
Needham analyst Y. Edwin Mok started Ichor Holdings with a Buy rating and $17 price target as he believes the company is well positioned to deliver continued growth in 2017 and 2018 given the stable growth industry environment, its high exposure to faster growing segments, and the "solid opportunities" for market share gains.
01/03/17
COWN
01/03/17
INITIATION
Target $15
COWN
Outperform
Ichor Holdings initiated with an Outperform at Cowen
Cowen analyst Timothy Acuri initiated Ichor Holdings with an Outperform rating citing its premium growth rate given its favorable customer exposure, some margin expansion, and new SAM expansion within semis and new verticals longer term. Acuri has a $15 price target on Ichor Holdings shares.
01/03/17
STFL
01/03/17
INITIATION
STFL
Buy
Ichor Holdings initiated with a Buy at Stifel
Stifel analyst Patrick Ho started coverage of Ichor with a $16 price target and a Buy rating.
MRK Merck
$59.92

-1.18 (-1.93%)

12/19/16
12/19/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Merck (MRK) downgraded to Underperform from Hold at Jefferies with analyst Jeffrey Holford saying he sees Pharmaceutical sector fundamentals weakening in 2017 amid political overhangs and an adverse macro environment. 2. Lowe's (LOW) downgraded to Neutral from Buy at Citi with analyst Kate McShane citing the potential for the company missing recently stated comp targets. 3. JAKKS Pacific (JAKK) was downgraded to Neutral from Overweight at Piper Jaffray and to Market Perform from Outperform at BMO Capital. 4. Sunoco (SUN) downgraded to Neutral from Buy at BofA/Merrill with analyst Gabe Moreen saying Moody's downgrade of Sunoco's debt to Ba2 to Ba3 reaffirms that its leverage is elevated and could continue to pressure its ability to deleverage near-term. 5. KeyCorp (KEY) downgraded to Equal Weight from Overweight at Stephens with analyst Terry McEvoy citing four total rate hikes occurring in the first and third quarter of 2017 and 2018. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/16/16
BARD
12/16/16
NO CHANGE
Target $100
BARD
Outperform
Gilead Hep C royalty to Merck looks increasingly likely, says Baird
After Merck (MRK) won its second Hep C patent infringement case against Gilead (GILD) this year and a jury awarded $2.54B in damages, Baird analyst Brian Skorney noted that Gilead plans to appeal but also said that a royalty looks increasingly likely. Skorney, who now assumes a 50% probability of the $2.54B payout and a 35% chance of a 10% royalty on Hep C sales in perpetuity, called the payout "chump change" for Gilead and said that a 10% royalty would provide a "modest drag" on Gilead's free cash. The analyst has an Outperform rating and $100 price target on Gilead shares.
01/09/17
PIPR
01/09/17
NO CHANGE
PIPR
Piper lists Pfizer, Lilly as top 2017 large-cap Pharma picks
Piper Jaffray analyst Richard Purkiss highlights Pfizer (PFE) and Eli Lilly (LLY) as his top large-cap Pharma picks in 2017,saying he prefers "cheaper growth names with limited event risk." With group earnings growth set to halve in 2017 as pipeline momentum stalls, the analyst sees "little likelihood" of sector outperformance. Purkiss calls Merck (MRK) and Johnson & Johnson (JNJ) his least preferred names in large-cap Pharma.
12/19/16
JEFF
12/19/16
DOWNGRADE
Target $48
JEFF
Underperform
Merck downgraded to Underperform from Hold at Jefferies
Jefferies analyst Jeffrey Holford downgraded Merck (MRK) to Underperform, his firm's sell-rating equivalent. The analyst sees Pharmaceutical sector fundamentals weakening in 2017 amid political overhangs and an adverse macro environment. Potential dual eligible rebate reform is the most significant risk, Holford tells investors in a research note. Specific to Merck, the analyst expects further pressure on Keytruda in 2018, driven by share losses in non-small cell lung cancer to Bristol-Myers Squibb (BMY), AstraZeneca (AZN) and Roche (RHHBY). Merck screens poorly on many valuation metrics, Holford contends. He lowered his price target for the shares to $48 from $59. The stock closed Friday up 7c to $62.44. The analyst this morning also upgraded both Bristol-Myers Squibb (BMY) and Bayer (BAYRY) to Buy from Hold. His top picks in Pharmaceuticals are AbbVie (ABBV) and Eli Lilly (LLY) for the U.S. and AstraZeneca and Novartis (NVS) in Europe.
UAL United Continental
$73.66

2.38 (3.34%)

01/04/17
01/04/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. JPMorgan analyst Richard Vosser downgraded Novartis (NVS) to Neutral from Overweight saying pressures on the company's business are mounting. The pressure from generic erosion in 2017 "remains high" with an estimated $2.3B of sales expected to be lost to generics, said Vosser, who sees "significant downside" to consensus estimates for Novartis. 2. BofA Merrill Lynch analyst Lisa Lewandowski downgraded Philip Morris (PM) to Neutral from Buy and lowered its price target to $96 from $102 citing concerns from the strong U.S. dollar, less impact from an overhaul in U.S. tax policy versus peers, underperformance in combustible tobacco volumes, increasing heat-not-burn competition, a rotation out of defensive/bond proxy assets, and debt convent constraints. 3. Jefferies analyst Andy Barish downgraded Dunkin' Brands (DNKN) to Underperform from Hold, saying he does not believe the company's same-store-sales have broken out above 2% while its international growth has been disappointing. Barish also downgraded Cheesecake Factory (CAKE) to Underperform, citing the 15% post-election rally with no change in fundamentals along with the company's "significant" mall exposure. 4. Evercore ISI downgraded Intuitive Surgical (ISRG) to Hold from Buy and lowered its price target to $690 from $780, with analyst Vijay Kumar saying he expects 2017 to be one of the most challenging for healthcare in general, with the sector facing issues ranging from ACA repeal to border tax reform to interest expense deductibility. 5. Cowen analyst Helane Becker downgraded a number of airline stocks, including United Continental (UAL), JetBlue (JBLU), Alaska Air (ALK) and American Airlines (AAL), to Market Perform from Outperform based on valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/05/17
01/05/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Macy's (M) downgraded to Hold from Buy at Deutsche Bank with analyst Paul Trussell saying the company's turnaround initiatives "continue to fall short of expectations." The "discouraging" 2017 forecast reflects the "realities of market share losses" to off-price retail, Amazon (AMZN) and other online threats, Trussell tells investors in a research note after Macy's lowered its outlook. He cut his price target for the shares to $34 from $47. 2. Kohl's (KSS) downgraded to Market Perform from Outperform at Telsey Advisory and to Neutral from Outperform at Baird. 3. DCP Midstream (DPM) downgraded to Sector Perform from Outperform at RBC Capital and to Underperform from Neutral at Credit Suisse. 4. United Continental (UAL) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Rajeev Lalwani saying he changed his rating due to relative outperformance and said further upside might be limited from here. 5. Travelers (TRV) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Kai Pan saying lower reserve releases and rising auto claims present a risk to earnings and post US election share strength underestimates these fundamental headwinds. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/05/17
MSCO
01/05/17
DOWNGRADE
Target $72
MSCO
Equal Weight
United Continental downgraded to Equal Weight on valuation at Morgan Stanley
Morgan Stanley analyst Rajeev Lalwani downgraded United Continental to Equal Weight from Overweight with a $72 price target. Analyst Rajeev Lalwani changed his rating due to relative outperformance and said further upside might be limited from here.
01/05/17
MSCO
01/05/17
DOWNGRADE
MSCO
Equal Weight
United Continental downgraded to Equal Weight from Overweight at Morgan Stanley
MX MagnaChip
$6.35

0.25 (4.10%)

09/28/16
ROTH
09/28/16
INITIATION
Target $10
ROTH
Buy
MagnaChip initiated with a Buy at Roth Capital
Roth Capital analyst Suji Desilva initiated Magnachip with a Buy rating and $10 price target, contending the company is now poised for growth and execution under its new management.
BRG Bluerock Residential
$13.84

-0.01 (-0.07%)

07/21/16
JMPS
07/21/16
INITIATION
JMPS
Outperform
Bluerock Residential initiated with an Outperform at JMP Securities
Target $16.
04/06/16
FBRC
04/06/16
INITIATION
Target $13
FBRC
Outperform
Bluerock Residential initiated with an Outperform at FBR Capital
FBR analyst Patrick Kealey initiated Bluerock Residential with an Outperform rating and $13 price target per share.
01/04/17
FBRC
01/04/17
DOWNGRADE
Target $14
FBRC
Market Perform
Bluerock Residential downgraded to Market Perform at FBR Capital
FBR Capital analyst David Corak downgraded Bluerock Residential to Market Perform from Outperform on expectations the company's markets are "poised to feel increasing supply pressure" in 2017. The analyst lowered his price target for the shares to $14 from $15.
PE Parsley Energy
$36.67

0.91 (2.54%)

10/12/16
MACQ
10/12/16
DOWNGRADE
Target $38
MACQ
Neutral
Parsley Energy downgraded to Neutral from Outperform at Macquarie
Macquarie analyst Paul Grigel downgraded Parsley Energy to Neutral citing strong share performance year-to-date and raised its price target to $38 from $36.
09/13/16
FBRC
09/13/16
INITIATION
Target $41
FBRC
Outperform
Parsley Energy initiated with an Outperform at FBR Capital
FBR Capital analyst Joseph Allman started Parsley Energy with an Outperform rating and $41 price target.
11/03/16
UBSW
11/03/16
NO CHANGE
Target $44
UBSW
Buy
Parsley Energy price target raised to $44 from $41 at UBS
UBS analyst William Janela raised his price target on Parsley Energy to $44 from $41 following its solid Q3 results. The analyst cited the company's raised production guidance and bullish operational update showing they remain on-track for significant growth in 2017. Janela reiterated his Buy rating on Parsley Energy shares.
12/15/16
DRXL
12/15/16
INITIATION
Target $44
DRXL
Buy
Parsley Energy initiated with a Buy at Drexel Hamilton
Drexel Hamilton analyst Robert Christensen initiated Parsley Energy with a Buy and a $44 price target.
VECO Veeco
$29.65

0.55 (1.89%)

08/02/16
DBAB
08/02/16
UPGRADE
Target $22
DBAB
Buy
Veeco upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Vishal Shah upgraded Veeco Instruments to Buy saying that while the Q2 results were soft, management suggested a meaningful improvement in MOCVD bookings environment in Q3. The analyst expects the stock's positive momentum to continue in the near term and he raised his price target for the name to $22 from $16.
11/02/16
PACS
11/02/16
NO CHANGE
PACS
Veeco executing well, says Pacific Crest
Pacific Crest analyst Daniel Baksht believes that Veeco is executing well as it wins new orders from LED chip manufacturers for additional capacity. The analyst thinks the company has leverage in its model and is one of the fastest growing equipment companies. He raised his price target on the stock to $26 from $24 and keeps an Overweight rating.
05/24/16
PACS
05/24/16
NO CHANGE
PACS
Veeco should maintain leadership after competitor acquired, says Pacific Crest
After Aixtron (AIXG) announced that it had agreed to be acquired by a Chinese investment fund, Pacific Crest says it's unsure about how the deal will affect Aixtron. However, the firm does not expect the deal to alter Veeco's (VECO) status as the market leader in developing equipment used by LED chip makers. It continues to recommend buying Veeco's stock and keeps a $23 price target o nthe shares.
11/02/16
UBSW
11/02/16
NO CHANGE
Target $27
UBSW
Buy
Veeco results show signs of LED equipment upcycle, says UBS
UBS analyst Stephen Chin said Veeco reported solid results and a better than expected outlook, which keeps him positive on the stock. The analyst said the company's outlook suggests the LED industry is in the early stages of an upcycle and he estimates that the company has significant operating leverage after all of its restructuring. Chin reiterated his Buy rating and raised his price target to $27 from $24.50 on Veeco shares.
JNPR Juniper
$28.40

0.01 (0.04%)

01/09/17
BERN
01/09/17
DOWNGRADE
BERN
Market Perform
Juniper downgraded to Market Perform from Outperform at Bernstein
Bernstein analyst Pierre Ferragu downgraded Juniper based on valuation. Target $33.
01/10/17
DBAB
01/10/17
DOWNGRADE
Target $21
DBAB
Sell
Juniper downgraded to Sell from Hold at Deutsche Bank
Deutsche Bank analyst Vijay Bhagavath downgraded Juniper to Sell from Hold and lowered his price target to $21 from $22.50 based on a lack of product revenue growth and structural headwinds for the company's routers, which leads Bhagavath to anticipate downward revisions to "current elevated street earnings estimates" on Juniper.
12/13/16
OTRG
12/13/16
UPGRADE
OTRG
Positive
Juniper upgraded to Positive from Mixed at OTR Global
OTR Global upgraded Juniper to Positive from Mixed following checks that indicate overall Q4 sales may exceed expectations due to increased sales at existing customers, Q4 switch sales exceeding expectations, higher QFX data center switch sales, and exceeding Pipelines.
12/08/16
12/08/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AMD (AMD) upgraded two notches to Buy from Underperform at BofA/Merrill with analyst Vivek Arya indicating that PC gaming and AI/Deep learning Industries are still in the early stages and AMD is a vendor that can challenge incumbents Intel (INTC) and NVIDIA (NVDA) for market share. 2. lululemon (LULU) upgraded to Buy from Sell at Evercore ISI, to Buy from Neutral at Mizuho, and to Neutral from Underperform at BofA/Merrill. 3. Hess Corp. (HES) upgraded to Overweight from Neutral at JPMorgan with analyst Arun Jayaram saying the company can post upside 2017 and 2018 oil growth versus expectations as it boosts Bakken activity levels. 4. Juniper (JNPR) upgraded to Buy from Neutral at Nomura with analyst Jeffrey Kvaal saying Juniper's new QFX family of data center switches is poised to grow rapidly in 2017 and total switching unit growth could be upwards of 12% in 2017. 5. Scotts Miracle-Gro (SMG) upgraded to Buy from Underperform at BofA/Merrill with analyst Christopher Carey saying Scotts has become a leader in hydroponics, a category primed to see significant growth for years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
VRX Valeant
$16.40

1.05 (6.84%)

01/04/17
PIPR
01/04/17
NO CHANGE
Target $11
PIPR
Underweight
Piper calls Valeant 'not investable,' cuts target to $11
Piper Jaffray analyst David Amsellem cut his price target for Valeant Pharmaceuticals to $11 from $16 and reiterates an Underweight rating on the shares. The drugmaker closed yesterday up 72c to $15.24. After taking a closer look at prescription trends across the company's U.S. business, Amsellem believes shares of Valeant are "not investable." The company faces "significant pressure" from generic competition on high-margin assets while the "picture on the whole continues to look challenging," the analyst tells investors in a research note. He believes the likelihood of "significant pressure on the shares is far higher than that of potential recovery."
01/10/17
WELS
01/10/17
NO CHANGE
WELS
Underperform
Valeant hiked prices on over 50 products last week, says Wells Fargo
Wells Fargo analyst David Maris said last night that on January 6, Valeant Pharmaceuticals implemented 95 different price increases across more than 50 products. This shows the company continues to rely on price as a means of growth and may also signal that Valeant's prescription volumes continue to remain challenged, Maris told investors in a research note. He reminds investors that Friday's price hikes "come on top of significant price increases--some of them more than 100%--taken on products in previous years and several taken in late 2016." Maris continues to believe the "new Valeant" is the "same Valeant using the same strategy and pricing levers that have been used before." The analyst keeps an Underperform rating on the shares with a $10-$13 price target range. The stock is up 12% to $17.20 in pre-market trading following the announcement of several asset sales.
01/10/17
BMOC
01/10/17
NO CHANGE
Target $21
BMOC
Market Perform
Valeant sales of Dendreon, CeraVe a 'good start,' says BMO Capital
BMO Capital analyst Gary Nachman said Valeant's (VRX) sales of Dendreon to Sanpower Group and CeraVe, AcneFree and AMBI to L'Oreal (LRLCY) for roughly $2.1B in cash have a combined average sales multiple of 4.4x, which appears to be a "solid price" and a good start for the company as it looks to sell additional assets to address its debt. Nachman also noted that Valeant announced that its second Phase 3 study for IDP-118 was successful, though he remains cautious on the drug given that most psoriasis creams are generic at this point. The analyst keeps a Market Perform rating and $21 price target on Valeant shares, which are up nearly 13% to $17.31 in pre-market trading.
01/10/17
01/10/17
NO CHANGE

Wells Fargo says Valeant debt problematic, base business still weak
Wells Fargo analyst David Maris said the proceeds announced today from Valeant's sale of its Dendreon unit, CeraVe and two other products would cover some, but not all, of the approximately $3.8B in debt the company has due in 2018. Valeant has not made clear in its press releases if these deals are dilutive to EPS, noted Maris, who believes the company's debt is problematic and base business remains weak. Maris keeps an Underperform rating on Valeant shares.

TODAY'S FREE FLY STORIES

HSY

Hershey

$107.44

0.34 (0.32%)

19:16
08/23/17
08/23
19:16
08/23/17
19:16
Hot Stocks
Hershey Company to acquire 1.5M common shares from Hershey Trust »

The Hershey Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSADY

MS&AD Insurance

$17.08

-0.085 (-0.50%)

19:07
08/23/17
08/23
19:07
08/23/17
19:07
Hot Stocks
MS&AD Insurance to acquire First Capital Insurance in $1.6B deal »

Fairfax Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$169.00

-1.07 (-0.63%)

18:46
08/23/17
08/23
18:46
08/23/17
18:46
Hot Stocks
Amgen: Lancet Oncology publishes survival analysis from KYPROLIS Phase 3 trial »

Amgen announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Sep

  • 11

    Sep

  • 14

    Sep

  • 02

    Dec

  • 03

    Feb

  • 17

    May

GE

General Electric

$24.39

-0.21 (-0.85%)

, ABB

ABB

$23.13

-0.01 (-0.04%)

18:39
08/23/17
08/23
18:39
08/23/17
18:39
Periodicals
GE resumes talks with ABB over industrial solutions deal, Reuters reports »

General Electric (GE) has…

GE

General Electric

$24.39

-0.21 (-0.85%)

ABB

ABB

$23.13

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 11

    Sep

  • 02

    Oct

LZB

La-Z-Boy

$24.95

-6.3 (-20.16%)

, AMZN

Amazon.com

$958.00

-8.9 (-0.92%)

18:17
08/23/17
08/23
18:17
08/23/17
18:17
Periodicals
La-Z-Boy in talks with Amazon over youth shopper outreach, MarketWatch reports »

La-Z-Boy (LZB) is in…

LZB

La-Z-Boy

$24.95

-6.3 (-20.16%)

AMZN

Amazon.com

$958.00

-8.9 (-0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 23

    Aug

  • 24

    Aug

  • 29

    Aug

VLKAY

Volkswagen

$30.67

0.19 (0.62%)

18:14
08/23/17
08/23
18:14
08/23/17
18:14
Periodicals
VW to launch two-tone compact SUV, Bloomberg says »

Volkswagen plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$10.71

0.06 (0.56%)

18:01
08/23/17
08/23
18:01
08/23/17
18:01
Hot Stocks
Ford names Jason Luo as chairman, CEO of Ford China »

Ford announced a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$238.09

-1.66 (-0.69%)

, LMT

Lockheed Martin

$302.84

-1.96 (-0.64%)

17:47
08/23/17
08/23
17:47
08/23/17
17:47
Periodicals
Boeing 'disappointed' company not chosen for cruise missile deal, Bloomberg says »

Lockheed (LMT), Raytheon…

BA

Boeing

$238.09

-1.66 (-0.69%)

LMT

Lockheed Martin

$302.84

-1.96 (-0.64%)

RTN

Raytheon

$178.19

-1.03 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

HBM

Hudbay Minerals

$8.50

0.2 (2.41%)

17:44
08/23/17
08/23
17:44
08/23/17
17:44
Hot Stocks
Hudbay Minerals acquires 10.76M common shares of Mason Resources »

Hudbay Minerals announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$18.86

-0.16 (-0.84%)

17:32
08/23/17
08/23
17:32
08/23/17
17:32
Hot Stocks
Breaking Hot Stocks news story on HP Inc. »

HP Inc. sees Q4 PC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 29

    Aug

  • 29

    Aug

  • 31

    Aug

  • 01

    Sep

  • 06

    Sep

GES

Guess

$12.48

0.11 (0.89%)

, TLYS

Tilly's

$9.60

0.88 (10.09%)

17:29
08/23/17
08/23
17:29
08/23/17
17:29
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Guess…

GES

Guess

$12.48

0.11 (0.89%)

TLYS

Tilly's

$9.60

0.88 (10.09%)

WSM

Williams-Sonoma

$43.40

0.55 (1.28%)

PVH

PVH Corp.

$120.04

-0.28 (-0.23%)

YUME

YuMe

$5.15

0.09 (1.78%)

HPQ

HP Inc.

$18.86

-0.16 (-0.84%)

HEI

Heico

$81.11

-0.95 (-1.16%)

GBT

Global Blood Therapeutics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 23

    Aug

  • 23

    Aug

  • 23

    Aug

  • 24

    Aug

  • 24

    Aug

  • 29

    Aug

  • 29

    Aug

  • 31

    Aug

  • 01

    Sep

  • 06

    Sep

  • 06

    Sep

  • 06

    Sep

  • 07

    Sep

  • 07

    Sep

  • 08

    Sep

  • 11

    Sep

  • 28

    Sep

MATX

Matson

$24.02

0.24 (1.01%)

17:28
08/23/17
08/23
17:28
08/23/17
17:28
Hot Stocks
Matson upgrading its Honolulu terminal »

Matson announced that a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$33.90

0.78 (2.36%)

17:24
08/23/17
08/23
17:24
08/23/17
17:24
Syndicate
Breaking Syndicate news story on Tactile Systems »

Tactile Systems files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$33.90

0.78 (2.36%)

17:23
08/23/17
08/23
17:23
08/23/17
17:23
Syndicate
Breaking Syndicate news story on Tactile Systems »

Tactile Systems files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIVI

Civitas Solutions

$18.30

-0.1 (-0.54%)

17:21
08/23/17
08/23
17:21
08/23/17
17:21
Recommendations
Civitas Solutions analyst commentary  »

Civitas announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLL

L3 Technologies

$179.28

-1.39 (-0.77%)

17:20
08/23/17
08/23
17:20
08/23/17
17:20
Hot Stocks
L3 Technologies awarded $172.9M government contract modification »

L-3 Communications Vertex…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$238.08

-1.67 (-0.70%)

17:19
08/23/17
08/23
17:19
08/23/17
17:19
Hot Stocks
Boeing awarded $222.5M government contract modification »

The Boeing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$178.19

-1.03 (-0.57%)

17:18
08/23/17
08/23
17:18
08/23/17
17:18
Hot Stocks
Raytheon awarded approximately $900M government contract »

Raytheon Co., Tucson,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$302.84

-1.96 (-0.64%)

17:17
08/23/17
08/23
17:17
08/23/17
17:17
Hot Stocks
Lockheed Martin awarded approximately $900M government contract »

Lockheed Martin Corp.,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

HPQ

HP Inc.

$18.86

-0.16 (-0.84%)

, SSNLF

Samsung

$2,020.00

-10 (-0.49%)

17:11
08/23/17
08/23
17:11
08/23/17
17:11
Hot Stocks
HP Inc. sees Samsung deal closing in Q4 »

HP Inc. (HPQ) said it saw…

HPQ

HP Inc.

$18.86

-0.16 (-0.84%)

SSNLF

Samsung

$2,020.00

-10 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 29

    Aug

  • 29

    Aug

  • 31

    Aug

  • 01

    Sep

  • 06

    Sep

HPQ

HP Inc.

$18.86

-0.16 (-0.84%)

17:09
08/23/17
08/23
17:09
08/23/17
17:09
Hot Stocks
HP Inc.: Company outgrew PC market unit growth in Q2 »

Says investing in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 29

    Aug

  • 29

    Aug

  • 31

    Aug

  • 01

    Sep

  • 06

    Sep

TDG

TransDigm

$271.82

-3.52 (-1.28%)

17:08
08/23/17
08/23
17:08
08/23/17
17:08
Hot Stocks
TransDigm declares special dividend of $22.00 per share »

TransDigm has authorized…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROG

Rogers Corporation

$115.31

-0.67 (-0.58%)

17:01
08/23/17
08/23
17:01
08/23/17
17:01
Hot Stocks
Rogers Corporation director sells 3,500 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 08

    Sep

  • 09

    Sep

GES

Guess

$12.48

0.11 (0.89%)

16:59
08/23/17
08/23
16:59
08/23/17
16:59
Hot Stocks
Breaking Hot Stocks news story on Guess »

Guess up 10% to $13.70…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 28

    Sep

HPQ

HP Inc.

$18.86

-0.16 (-0.84%)

16:56
08/23/17
08/23
16:56
08/23/17
16:56
Hot Stocks
HP Inc. raises FY17 free cash flow view to at least $3B from $2.3B-$2.6B »

Guidance taken from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 29

    Aug

  • 29

    Aug

  • 31

    Aug

  • 01

    Sep

  • 06

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.